Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents

Yaoxue Xuebao

Volumn 45, Issue 3, 2010, Pages 283-288

  Cai, Yu Chen ^a   Zou, Yong ^b   Xian, Li Jian ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU INSTITUTE OF CHEMISTRY   (China)

Author keywords

Anti tumor activity; Tubulin binding agent; Vascular disrupting agent

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CA 4P; COLCHICINE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; N ACETYLCOLCHINOL PHOSPHATE; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SOBLIDOTIN; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; VINBLASTINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; DRUG MECHANISM; ENDOTHELIUM CELL; REVIEW; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIBENZYLS; DIPHOSPHATES; ENDOTHELIAL CELLS; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGANOPHOSPHORUS COMPOUNDS; SERINE; STILBENES; TUBULIN MODULATORS; XANTHONES;

EID: 77952185880     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumor therapy [J]. Br J Cancer, 1982, 45: 136-139. (Pubitemid 12207761)
2. Patherson DM, Rustin GJ. Vascular damaging agents [J]. Clin Oncol (R Coll Radiol), 2007, 19: 443-456.
3. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies [J]. Clin Cancer Res, 2005, 11: 416-420.
4. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent [J]. Int J Radiat Oncol Biol Phys, 2002, 54: 1491-1496. (Pubitemid 35380054)
5. Pettit GR, Rhodes MR, Herald DL, et al. Antineoplastic agents. 445. Synthesis and evaluation of structural modifications of (Z)- and (E)-combretastatin A-41 [J]. J Med Chem, 2005, 48: 4087-4099.
6. Thorpe PE. Vascular targeting agents as cancer therapeutics [J]. Clin Cancer Res, 2004, 10: 415-427. (Pubitemid 38173977)
7. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents [J]. Bioassays, 1991, 13: 31-36.
8. Sun CM, Lin LG, Yu HJ, et al. Synthesis and cytotoxic activities of 4,5-diarylisoxazoles [J]. Bioorg Med Chem Lett, 2007, 17: 1078-1081.
9. Chaplin DJ, Horsman MR. The influence of tumour temperature on ischemia-induced cell death: potential implications for the evaluation of vascular mediated therapies [J]. Radiother Oncol, 1994, 30: 59-65.
10. Robinson SP, Mcintyre DJ, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging [J]. Br J Cancer, 2003, 88: 1592-1597. (Pubitemid 36713788)
11. West CM, Price P. Combretastatin A4 phosphate [J]. Anticancer Drugs, 2004, 15: 179-187.
12. Jameson MB, Thompson PI, Baguley BC, et al. Phase I/II Trials Committee of Cancer Research UK. Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent [J]. Br J Cancer, 2003, 88: 1844-1850.
13. Monk KA, Siles R, Hadimani MB, et al. Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents [J]. Bioorg Med Chem, 2006, 14: 3231-3244.
14. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent [J]. Cancer Res, 2003, 63: 1534-1537. (Pubitemid 36373640)
15. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126 [J]. Clin Cancer Res, 2004, 10: 3650-3657. (Pubitemid 38697598)
16. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126 [J]. Int J Radiat Oncol Biol Phys, 2002, 54: 1512-1517.
17. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors [J]. Int J Radiat Oncol Biol Phys, 2005, 62: 846-853.
18. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response [J]. Int J Radiat Oncol Biol Phys, 2003, 57: 1047-1055. (Pubitemid 37324123)
19. Schöffski P, Thate B, Beutel G, et al. Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer [J]. Ann Oncol, 2004, 15: 671-679. (Pubitemid 38559607)
20. Riely GJ, Gadgeel S, Rothman I, et al. A phase 2 study of TZT-1027, administered weekly to patients with advanced nonsmall cell lung cancer following treatment with platinum-based chemotherapy [J]. Lung Cancer, 2007, 55: 181-185. (Pubitemid 46074222)
21. Pettit GR, Temple C Jr, Narayanan VL, et al. Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs [J]. Anticancer Drug Design, 1995, 10: 299-309.
22. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow [J]. J Clin Oncol, 2003, 21: 4428-4438. (Pubitemid 46621821)
23. Landuyt W, Verdoes O, Darius DO, et al. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas [J]. Eur J Cancer, 2000, 36: 1833-1843.
24. Salmon BA, Siemann DW. Characterizing the tumor response to treatment with combretastatin A4 phosphate [J]. Int J Radiat Oncol Biol Phys, 2007, 68: 211-217.
25. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results [J]. J Clin Oncol, 2003, 21: 2815-2822. (Pubitemid 46621828)
26. Hori K. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE-8062 (AC7700) [J]. Chemotherapy, 2005, 51: 357-360. (Pubitemid 41546713)
27. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE-8062) induces tumour blood flow stasis [J]. Br J Cancer, 2003, 89: 1334-1344. (Pubitemid 37363426)
28. Hori K, Saito S, Sato Y, et al. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: implications for the evaluation of therapeutic efficacy of AC7700 (AVE-8062) [J]. Eur J Cancer, 2003, 39: 1957-1966.
29. Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity [J]. Clin Cancer Res, 2006, 12: 4090-4094.
30. Hill SA, Toze GM, Pettit GR, et al. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503 [J]. Anticancer Res, 2002, 22: 1453-1458.
31. Holwell SE, Cooper PA, Thompson MJ, et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate [J]. Anticancer Res, 2002, 22: 3933-3940. (Pubitemid 36134416)
32. Kirwan IG, Loadman PM, Swaine DJ, et al. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate [J]. Clin Cancer Res, 2004, 10: 1446-1453.
33. Folkes LK, Christlieb M, Madej E, et al. Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals [J]. Chem Res Toxicol, 2007, 20: 1885-1894.